Ephrin-A1 expression is significantly downregulated in glioma cell lines and primary gliomas compared to normal brain tissue (Hao et al., 2021; Liu et al., 2007). In low-grade gliomas, higher ephrin-A1 levels are associated with increased infiltration of CD4⁺ T cells, myeloid dendritic cells, and neutrophils. Additionally, tumors with high ephrin-A1 expression are enriched for genes involved in the intrinsic apoptotic pathway, suggesting a tumor-suppressive and immunomodulatory role (Hao et al., 2021; Table 2; Figure 1).

Functional studies support this interpretation. In U251 glioma cells, forced expression of ephrin-A1 significantly inhibited migration, proliferation, and anchorage-independent growth. These effects agreed with decreased levels of EphA2 and its downstream effector FAK, indicating that ephrin-A1 suppresses glioma progression via inhibition of the EphA2-FAK signaling axis (Liu et al., 2007).

Therapeutic strategies have been developed to harness ephrin-A1's antitumor properties. One study used bacterial cytotoxins fused to ephrin-A1 and IL-13 mutants, targeting EphA2 and IL13RA2 via convection-enhanced delivery in dogs with intracranial gliomas. The approach achieved broad intratumoral distribution (median coverage: 70%; range: 40–94%), was well tolerated, and produced objective tumor responses in 50% (8/16) of cases, with tumor volume reductions of up to 94% (Rossmeisl et al., 2021).

Another study used an adenovirus vector delivering an ephrinA1-PE38 fusion protein with GM-CSF elicited strong antitumor activity in glioma-bearing rats. Treatment reduced tumor volume, extended survival, and activated dendritic cells, suggesting the creation of in situ dendritic cell vaccines. This strategy offers localized and systemic immune responses while avoiding the limitations of ex vivo dendritic cell manipulation (Li et al., 2015b).

Building on this, chitosan-coated nanoparticles delivering the same ephrinA1-PE38/GM-CSF construct showed enhanced dendritic cell activation, tumor eradication, and prolonged survival in glioma models, highlighting their promise for personalized immunotherapy (Li et al., 2015a).

Finally, human mesenchymal stem cells (hMSCs) engineered to secrete ephrinA1-PE38 selectively targeted EphA2-overexpressing glioma cells. Intratumoral injection of these hMSCs suppressed tumor growth in vivo, supporting stem cell-based gene delivery as a viable and targeted treatment strategy for malignant gliomas (Sun et al., 2011).

EphA2 is overexpressed in approximately 67% of glioma patients and is inversely correlated with overall survival, making it a key prognostic marker alongside VEGF and vWF (Shen et al., 2021). Its expression increases with tumor grade and predicts poor prognosis, while higher levels of ephrin-A1 are associated with lower-grade tumors. Patients with EphA2-positive/ephrin-A1-negative tumors have significantly worse overall and progression-free survival (Li et al., 2010).

In glioma stem cells (GSCs), EphA2 promotes invasion through Akt-mediated phosphorylation at serine 897. This signaling remains active without ligand binding but is suppressed by ephrin-A ligands. In EphrnA1/3/4 triple-knockout mice, GSC invasion increased, while EphA2 knockdown reduced self-renewal, stemness, and tumorigenicity. Notably, EphA2 enhances stem-like traits independent of its kinase activity, while disruption of the Akt-EphA2 axis impairs neurosphere formation (Miao et al., 2015).

Immunohistochemical studies in glioma patients showed significantly higher expression of EphA2 (90.91%) and MMP-2 (86.36%) in high-grade tumors compared to low-grade cases. MRI features such as peritumoral edema, contrast enhancement, and tumor size also correlated with EphA2 and MMP-2 expression, reinforcing their role in glioma invasiveness (Suo et al., 2019).

EphA2 is overexpressed in roughly 90% of GBM cases and is significantly elevated compared to normal brain tissue and lower-grade gliomas. In contrast, ephrin-A1 levels are often low. Activation of EphA2 by ephrin-A1 suppresses anchorage-independent growth and invasion in a dose-dependent manner, confirming its oncogenic role and therapeutic potential (Wykosky et al., 2005; Figure 2).

Within GBM tumor-propagating cells (TPCs), EphA2 expression correlates with higher tumorigenicity. Knockdown of EphA2 or treatment with ephrinA1-Fc impairs self-renewal and tumor growth (Binda et al., 2012). In recurrent GBM, coexpression of EphA2 and EphA3 marks a highly tumorigenic GSC subpopulation. Dual knockdown promotes differentiation and prevents tumor formation, while a bispecific antibody targeting both receptors significantly reduces tumor burden (Qazi et al., 2018).

EphA2 also interacts with integrin α3 at the cell periphery in U251MG cells, contributing to migration and adhesion via focal adhesion complexes (Makarov et al., 2013). Functionally, EphA2 acts downstream of MEK/ERK/RSK signaling, where EGF induces its S897 phosphorylation. This is blocked by MEK or RSK inhibitors and reduced by ephrin-A1 or EphA2 knockdown (Hamaoka et al., 2016). Interestingly, a Wnt5a^∧High/EphA2^∧Low GSC subpopulation was more tumorigenic than Wnt5a^∧Low/EphA2^∧High cells, and combined inhibition of Wnt5a and EphA2 drastically reduced invasion and tumor growth (Trivieri et al., 2022).

Several therapeutic approaches have been developed to target EphA2. Filamin A forms a complex with EphA2, promoting its phosphorylation and GBM cell proliferation. Silencing filamin A blocks EGF-induced activation and tumor growth (Tamura et al., 2022). RNA aptamers such as 40L and A40s selectively bind EphA2, inhibiting GSC proliferation and migration. A40s are particularly promising due to their serum stability and ability to cross the blood-brain barrier (Affinito et al., 2020).

The small-molecule inhibitor GLPG1790 blocks EphA2 phosphorylation at Tyr588 and Ser897, modulates differentiation markers, and reduces tumor growth, showing synergy with standard therapies (Gravina et al., 2019).

EphA2-directed CAR T cells enhance anti-tumor responses by increasing IFN-γ and OX40 expression, and their efficacy improves further when combined with PD-1 blockade (An et al., 2021). Finally, UniPR1454, a novel l-β-homotryptophan derivative, inhibits EphA2/ephrin-A1 interaction and significantly reduces GBM cell proliferation (Guidetti et al., 2024).

EphA3, a receptor tyrosine kinase, is frequently overexpressed in gliomas, especially in GBM and its mesenchymal subtype. It is enriched in tumor-initiating cells, where it helps maintain an undifferentiated, stem-like state by modulating MAPK signaling. Suppressing EphA3, via gene silencing or radiolabeled monoclonal antibodies, significantly reduces tumorigenicity (Day et al., 2013).

Targeting EphA3 with CAR T cells has shown potent and specific cytotoxicity against GBM and diffuse midline glioma (DMG) cells in vitro. In orthotopic xenograft models, these cells eradicate tumors and induce durable immune memory. Notably, mice rechallenged with tumors on the contralateral side remained tumor-free for over 6 months, underscoring the therapeutic potential of EphA3-directed immunotherapy (Lertsumitkul et al., 2024).

EphA3 is detected in up to 60% of GBM samples and is particularly enriched in invasive fronts, perivascular niches, and tumor-infiltrating immune cells. A cytotoxic fusion protein based on ephrin-A5, which targets EphA3, EphA2, and EphB2, selectively kills GBM cells with remarkable potency (IC₅₀ ≈ 10⁻¹¹ M; Ferluga et al., 2016).

Further validating its therapeutic relevance, EphA3-directed CAR T cells generated from healthy donors effectively eliminate EphA3-positive GBM cells, patient-derived neurospheres, and organoids. These CAR T cells produce curative responses in orthotopic GBM models. Complementing this approach, a multivalent conjugate (QUAD 3.0) targeting EphA3, EphA2, EphB2, and IL13RA2 was developed. Linked to doxorubicin derivatives, this construct binds all four receptors with nanomolar affinity and delivers cytotoxic agents to tumor cells with minimal toxicity in vivo (Sharma et al., 2020).

To bypass the blood-brain barrier, temozolomide-conjugated gold nanoparticles functionalized with anti-EphA3 antibodies have been engineered for intranasal delivery. This formulation improves drug uptake, enhances apoptosis in glioma cells, and lowers IC50 by 18.5-fold in TMZ-resistant GBM models, significantly extending survival in treated animals (Wang et al., 2021).

EphA4 mRNA is expressed at levels four times higher in gliomas than in normal brain tissue. In U251 cells, EphA4 promotes proliferation and migration by enhancing FGF2-induced MAPK and Akt signaling and activating Rac1/Cdc42. Its physical interaction with FGFR1 further amplifies these oncogenic pathways (Fukai et al., 2008).

Also, EphA4 acts as a dependence receptor, inducing apoptosis in the absence of its ligand ephrin-B3. In GBM, elevated ephrin-B3 expression suppresses this pro-apoptotic signal, promoting the survival of both tumor and endothelial cells. Silencing ephrin-B3 reduces angiogenesis and tumor growth, highlighting the therapeutic potential of disrupting the EphA4/ephrin-B3 axis (Royet et al., 2017).

Ephrin-A5 is significantly downregulated in primary gliomas. Its forced expression in U373 cells suppresses tumorigenicity by promoting c-Cbl-mediated ubiquitination and degradation of EGFR, leading to reduced receptor levels. Similar effects are achieved using ephrinA5-Fc or EphA2-Fc, reinforcing its tumor-suppressive role (Li et al., 2009).

This suppression is epigenetically regulated. Bmi1 represses ephrin-A5 by inducing H3K27me3 enrichment at its promoter region, thereby enhancing GBM cell proliferation and invasion. This mechanism is active in glioma-initiating cells (GICs), suggesting that restoring ephrin-A5 signaling or targeting the Bmi1-ephrinA5 axis may represent a promising therapeutic strategy for Bmi1-overexpressing GBMs (Ricci et al., 2020).

Ephrin-A6 is downregulated in GBM but correlates with improved patient prognosis. Although bone morphogenetic protein (BMP) signaling promotes differentiation and apoptosis in glioma-initiating cells (GICs), some subpopulations are resistant. Ephrin-A6 enhances BMP-2-induced apoptosis in both BMP-sensitive and -resistant GICs, highlighting its therapeutic potential in overcoming BMP resistance (Raja et al., 2019).

Elevated EphA7 protein expression in GBM is associated with poor clinical outcomes, especially when accompanied by high microvascular density. Immunohistochemical evaluation of EphA7 offers valuable prognostic insight and may serve as a surrogate marker to identify patients who could benefit from tyrosine kinase inhibitor therapy (Wang et al., 2008).

Ephrin-B1 is consistently upregulated in gliomas, where it promotes tumor progression by enhancing proliferation, migration, and invasion. Its expression correlates with poor prognosis and advanced disease stages. Silencing ephrin-B1 suppresses these malignant traits, underscoring its functional relevance. Beyond its role in tumor cell behavior, ephrin-B1 is associated with immunological changes in the tumor microenvironment, including increased infiltration of Th2 cells, macrophages, and plasmacytoid dendritic cells (pDCs). It is also linked to oncogenic pathways such as cell cycle regulation, protein processing, and viral infection responses (Zheng and Shi, 2025).

In GBM, high ephrin-B1 expression independently predicts poor overall survival. A prognostic model incorporating ephrin-B1-associated immune modulators effectively stratifies patient outcomes. Functionally, ephrin-B1 silencing reduces GBM cell proliferation and migration, further supporting its oncogenic and immunomodulatory roles in high-grade gliomas (Shi et al., 2021).

In contrast, EphB1 appears to play a tumor-suppressive role. Although EphB1 expression levels are similar across glioma grades, only EphB1 is associated with improved survival in malignant gliomas. Mechanistically, EphB1 lacks detectable tyrosine phosphorylation in glioma cells and, when overexpressed, inhibits ephrin-B2-induced migration and invasion both in vitro and in vivo (Teng et al., 2013).

EphB2 is overexpressed in glioma cells and plays a central role in tumor invasion and migration. In U87 cells, it localizes to lamellipodia during migration and promotes motility when activated. Its overexpression in U251 cells enhances invasion and reduces cell adhesion, confirming its pro-invasive function. These effects are mediated through R-Ras signaling, which regulates adhesion, proliferation, and invasion. Silencing R-Ras blocks EphB2 activity, and its phosphorylation correlates with tumor grade and EphB2 expression, reinforcing this invasive pathway (Nakada et al., 2004).

EphB2 is also stabilized under hypoxia by HIF-2α and promotes GBM cell invasion via paxillin phosphorylation, suggesting a HIF-2α-EphB2-paxillin axis that supports epithelial-mesenchymal transition (EMT) and tumor aggressiveness (Qiu et al., 2019). The ephrin-B2 ligand is equally critical, particularly in glioma stem-like cells (GSCs), where it drives perivascular invasion and homotypic migration via RhoA activation. Upregulation of ephrin-B2 enhances tumor initiation, while its inhibition, genetic or antibody-mediated, significantly impairs tumor progression in preclinical models (Krusche et al., 2016).

Clinically, ephrin-B2 expression correlates with high tumor grade and lower Karnofsky performance scores, serving as an independent prognostic marker for shorter progression-free survival (Tu et al., 2012). Similarly, ephrin-B2 mRNA levels are elevated in GBM compared to normal brain, and its expression is higher in invasive cell lines like U87. Functional studies show that ephrin-B2 promotes migration and invasion, and its blockade significantly suppresses these malignant behaviors (Nakada et al., 2004).

In GBM, ephrin-B2 is not only upregulated but also highly phosphorylated, indicating active signaling. It localizes to both tumor cells and vasculature, and endothelial-specific deletion reduces tumor growth and perfusion, mimicking antiangiogenic therapy. However, no additive benefit is seen when combined with VEGFR2 inhibition, suggesting shared angiogenic pathways (Broggini et al., 2022).

Interestingly, ephrin-B2 knockdown in GBM xenografts paradoxically increases tumor growth. This is reversed by ephrin-B2-Fc treatment, which activates EphB4 signaling. EphB4 activation inhibits proliferation and invasion, indicating a complex ephrin-B2-EphB4 regulatory axis that could be exploited therapeutically through simultaneous ephrin-B2 inhibition and EphB4 stimulation (Bhatia et al., 2020).

Moreover, in mouse models, EphB2 overexpression in Ink4a/Arf(–/–) neural stem cells induces ependymoma formation by enhancing proliferation, suppressing differentiation, and activating Ras and p38 MAPK signaling, highlighting its role in maintaining a stem-like, tumorigenic phenotype (Chen et al., 2015).

EphB3 expression inversely correlates with glioma aggressiveness, decreasing progressively with tumor grade. In glioma cell lines such as U87MG and U251, low EphB3 levels are associated with increased proliferation, migration, and invasion, primarily through upregulation of EGFR and activation of the PI3K/AKT signaling pathway. Conversely, EphB3 overexpression suppresses these malignant traits by downregulating this pathway, indicating its tumor-suppressive role and highlighting its potential as a diagnostic and therapeutic target (Xiao et al., 2024).

Ephrin-B3 plays a complementary pro-invasive role. It is upregulated in migrating cells from various glioma lines and invading cells from patient-derived biopsies. In functional studies, ephrin-B3 overexpression in low-expressing cell lines (U87, T98G) promotes invasion and migration, while its knockdown in high-expressing lines (U251, SNB19) reduces motility and disrupts Rac1-dependent lamellipodia formation. Notably, ephrin-B3 is essential for EphB2/Fc-induced invasion, reinforcing its role in glioma cell motility. In patient tumors, ephrin-B3 expression and phosphorylation levels correlate with histological grade and are enriched in invasive glioblastoma cells (Nakada et al., 2006).

EphB4 acts as a negative regulator of glioma progression. Stimulation of glioma cells with their specific ligand, ephrin-B2, induces EphB4 phosphorylation, which suppresses migration, invasion, and Akt signaling. These inhibitory effects are abolished by EphB4 silencing, underscoring its functional role in restraining malignancy. Immunostaining studies show EphB4 expression is localized to the tumor core, while ephrin-B2 is more widely distributed, suggesting that EphB4-ephrin-B2 interactions may help retain tumor cells centrally and limit peripheral invasion (Kawahara et al., 2019).

Beyond its role in cell motility, EphB4 also contributes to glioma vascular remodeling. Its overexpression leads to the development of large, treatment-resistant blood vessels by altering pericyte-endothelial interactions and vascular architecture. Co-localization of EphB4/ephrin-B2 with CD34 in stromal microvessels and GFAP in tumor cells has been observed, with higher expression levels in poorly differentiated tumors, reinforcing its relevance to both tumor aggressiveness and vascular pathology (Uhl et al., 2018; Xiao et al., 2004).

EphB6 is preferentially expressed in malignant gliomas, and a unique secretory variant, undetectable in normal tissue, has been identified by RT-PCR in most glioma cell lines. This isoform includes a distinct 54-amino acid sequence, from which peptides were shown to bind HLA-A2402 and elicit peptide-specific CD8⁺ cytotoxic T lymphocytes (CTLs) in HLA-A24⁺ glioma patients. These CTLs exert HLA-A24-restricted cytotoxicity, positioning EphB6 variant peptides as promising candidates for peptide-based immunotherapy in this subgroup of patients (Jin et al., 2008).

Complementing this immunotherapeutic potential, UniPR1331, a pan-Eph receptor antagonist, demonstrates strong anti-angiogenic and anti-tumor activity in GBM xenograft and orthotopic models. Treatment significantly reduces tumor volume and extends disease-free survival. When combined with Bevacizumab, UniPR1331 shows enhanced therapeutic efficacy, highlighting the value of Eph-targeted strategies in glioblastoma treatment (Festuccia et al., 2018).

EphA1 expression is reduced in medulloblastoma cell lines (DAOY, Res-220, Res-256, Uw-426, Uw-473, Uw-402) compared to normal fetal brain and adult cerebellum. Phosphorylation analysis revealed minimal EphA1 activation under basal conditions, with only a slight increase observed in Uw-402 cells. Stimulation with ephrin-A1 failed to elicit notable phenotypic effects, whereas ephrin-B1 induced modest activation of type A Eph receptors in Uw-402, suggesting cross-reactivity and ligand promiscuity within the Eph/ephrin system in medulloblastoma (Sikkema et al., 2012).

Furthermore, ephrin-A1 expression appears largely confined to non-SHH medulloblastoma subtypes, with minimal or absent expression in SHH-driven tumors. This subtype-specific expression pattern suggests a potential role for ephrin-A1 in non-SHH medulloblastoma biology, although its functional significance remains unclear (McKinney et al., 2015; Figure 3).

EphA2 is highly expressed in medulloblastoma cell lines Res-300 and Uw-426, with moderate phosphorylation detected in Uw-402 following stimulation (Sikkema et al., 2012). Although EphA2 signaling is generally associated with tumor-suppressive effects, its activation in this context may paradoxically promote angiogenesis via VEGF-A and TNF, likely influenced by high ephrin-A1 expression in endothelial cells. Supporting this, microarray data from 29 medulloblastoma samples revealed subgroup-specific expression patterns: EphA2 is enriched in non-SHH tumors (WHO groups 3 and 4) but absent in SHH subtypes, suggesting a potential role in the pathobiology of more aggressive medulloblastoma variants (Morrison et al., 2013).

EphA3 expression is elevated in primary medulloblastomas compared to normal cerebellum, with the highest levels observed in the Uw-402 cell line and normal fetal brain, suggesting its involvement in both neural development and tumor biology (Sikkema et al., 2012). Similarly, ephrin-A3 is predominantly expressed in non-SHH medulloblastomas, showing diffuse immunopositivity in over 95% of confirmed cases. Although ephrin-A3 may serve as a secondary ligand for receptors like EphB1, there is currently no direct evidence supporting its oncogenic activity (McKinney et al., 2015).

EphA4 expression is consistently reduced in medulloblastoma cell lines compared to normal brain tissue (Sikkema et al., 2012). However, knockout studies in mouse models lacking EphA4 and EphA7 revealed no significant impact on tumor size, suggesting that these receptors may not play a central role in tumor growth (Bhatia et al., 2015). In contrast, ephrin-A4 is predominantly expressed in SHH-subtype medulloblastomas, indicating a possible subtype-specific function that remains to be clarified (Bhatia et al., 2015).

EphA5 is highly expressed in the Uw-402 medulloblastoma cell line and normal fetal brain, suggesting a role in both cerebellar development and tumorigenesis (Sikkema et al., 2012). In ND2-SmoA1 transgenic mice, loss of ephrin-A5—along with EphA4 and EphA7—significantly reduced tumor size and p-Akt levels. Larger tumors in wild-type mice showed increased p-Akt and PCNA, implicating ephrin-A5 as a promoter of medulloblastoma growth via Akt pathway activation. Notably, only complete ephrin-A5 deletion suppressed tumor progression (Bhatia et al., 2015).

EphA6 exhibits subtype-specific expression in medulloblastoma, particularly enriched in subtype D, where it correlates with genes linked to axonal guidance and neuronal differentiation, such as Ephrin-B1, RND1, RND2, and SEMA3A. These associations suggest a role for EphA6 in regulating neuronal architecture and cellular organization within the tumor microenvironment, potentially influencing migration and tumor progression (Gokhale et al., 2010). However, expression analyses in medulloblastoma cell lines revealed reduced ephrin-A6 levels compared to normal tissue, implying suppression of its homeostatic neuronal functions in the malignant setting (Sikkema et al., 2012).

EphA7 expression is markedly reduced in medulloblastoma cell lines relative to normal tissue, indicating a distinct role in tumor biology (Sikkema et al., 2012). In double knockout mice lacking EphA4 and EphA7 (EphA4⁻/⁻ EphA7⁻/⁻ Smo), MRI and Western blot analyses showed no consistent changes in tumor size, despite correlations between tumor volume, p-Akt, and PCNA levels. The inability to generate EphA7 single knockout mice due to severe phenotypes limits further functional studies. These findings suggest that EphA7, a high-affinity receptor for ephrin-A5, may have redundant roles with other Eph receptors in medulloblastoma progression, though its exact function remains to be clarified (Bhatia et al., 2015).

EphA8 is significantly overexpressed in primary medulloblastoma tissues compared to normal cerebellum, suggesting a role in tumor-specific biology (Sikkema et al., 2012). Multiple studies have linked EphA8 expression to medulloblastoma subtypes associated with neuronal migration pathways and poor prognosis. Gokhale et al. (2010) and Kool et al. (2008) identified its expression mainly in subtypes C and D, while Kool also reported involvement in subtype E—subgroups typically classified as non-WNT/non-SHH tumors. Supporting this, McKinney et al. (2015) observed EphA8 expression to be largely restricted to non-SHH subtypes, reinforcing its relevance to their molecular landscape, although its precise functional contribution remains to be elucidated.

EphB1 is frequently expressed in medulloblastoma, particularly in SHH and non-SHH subtypes, with over 90% of tumors showing diffuse immunopositivity. Its expression is prominent in DAOY and D556 cell lines and absent in fetal cerebellum, indicating a tumor-specific profile (McKinney et al., 2015).

Functionally, EphB1 promotes tumor aggressiveness. In DAOY and UW228 cells, siRNA-mediated knockdown reduced EphB1 expression, leading to impaired migration, downregulation of β1-integrin and p-Src, increased G1 arrest, and enhanced radiosensitivity. Silencing EphB1 also delayed tumor recurrence after irradiation, indicating its role in cell cycle progression and resistance to therapy (Bhatia et al., 2015).

Transcriptomic analyses revealed EphB1 enrichment in tumor spheres with high self-renewal and in migrating cells, supporting its role in motility and stemness (Morrison et al., 2013). EphB1 is also upregulated in subtype D medulloblastomas, which are characterized by axon guidance and neuronal differentiation signatures, suggesting its involvement in tumor plasticity (Gokhale et al., 2010).

EphB1 is co-expressed with genes such as ephrin-B1, RND1/2, and SEMA3A, key regulators of neuronal migration, synaptogenesis, and axonal development, indicating that neurodevelopmental pathways may be hijacked to support tumor growth (Gokhale et al., 2010; Kool et al., 2008).

Among these genes, ephrin-B1 plays a key role by activating EphB1 independently of Src. Its overexpression increases EphB1/B2 phosphorylation, remodels the cytoskeleton, reduces adhesion, enhances proliferation, and alters migratory behavior. Ephrin-B1 knockdown impairs migration, potentially via STAT3 or Par-6 signaling, pointing to non-canonical pathways underlying its oncogenic effects (McKinney et al., 2015).

Ephrin-B1 is enriched in highly proliferative, dense tumor regions but absent in the fetal cerebellum, reinforcing its tumor-specific function. Functionally, ephrin-B1 modulates multiple pathways, including p38, MSK1/2, Stat1/2/4/5a/6, and paxillin, following ligand stimulation or EphB2 inhibition, suggesting broad influence over tumor behavior (Sikkema et al., 2012).

Despite its generally high levels of expression, some studies report reduced EphB1 levels in specific medulloblastoma lines (DAOY, Res-220, UW-426) compared to normal cerebellum, suggesting context-dependent regulation or inhibitory mechanisms within certain tumor environments (Sikkema et al., 2012).

EphB2 is upregulated in primary medulloblastomas compared to normal cerebellum, with high expression observed in DAOY and Res-300 cell lines. Functionally, ephrin-B1, but not ephrin-A1, enhanced invasion in DAOY and, to a lesser extent, in UW-402 cells, which express intermediate levels of EphB2. No effect was seen in Res-256 cells with low EphB2 expression. Ephrin-B1 also reduced adhesion to collagen (DAOY and UW-402) and laminin (DAOY only). These effects were reversed by EphB2 knockdown, confirming its role in promoting invasiveness and reducing adhesion (Sikkema et al., 2012).

Mechanistically, ephrin-B1 stimulation increased EphB2 phosphorylation and activated PI3K-Akt-mTOR and Ras-Raf-MEK-Erk pathways. In contrast, EphB2 silencing elevated phosphorylation of Erk1/2, mTOR, p27, and paxillin, indicating that EphB2 tightly regulates cell motility through multiple signaling nodes. These findings position EphB2 as a promising therapeutic target to limit medulloblastoma invasion. Additional studies support EphB2's relevance. Kool et al. (2008) confirmed its overexpression in tumors relative to normal cerebellum, and Morrison et al. (2013) showed EphB2 transcript enrichment in migrating DAOY cells but downregulation in self-renewing tumor spheres, highlighting its specific role in motility over stemness.

In a larger cohort, EphB2 was expressed in over 95% of tumors, with its phosphorylation dependent on ephrin-B1 and ephrin-B2 co-activation (McKinney et al., 2015). While tumor-specific and active in forward signaling, EphB2 does not appear to function as a primary oncogenic driver, suggesting that targeting both receptor and ligand may be necessary to disrupt its pro-invasive effects.

Ephrin-B2 contributes to this axis, with elevated expression in DAOY cells and the fetal brain compared to adult cerebellum (Sikkema et al., 2012). Detected in over 95% of medulloblastomas and fetal Purkinje cells, ephrin-B2 shows diffuse immunopositivity. Although its knockdown significantly reduced EphB1/B2 and Src phosphorylation, it did not affect proliferation, suggesting that ephrin-B2 supports classical Eph signaling without directly driving oncogenesis (McKinney et al., 2015).

EphB3 expression is consistently downregulated in medulloblastoma. qPCR analysis revealed reduced EphB3 levels in migratory cells compared to central tumor regions, and in low vs. high self-renewing tumor spheres, suggesting a context-dependent, potentially suppressive role within the Eph-ephrin axis (Morrison et al., 2013). This downregulation is further supported by decreased EphB3 mRNA levels across multiple medulloblastoma cell lines (DAOY, Res-220, Res-256, UW-426, UW-473, and UW-402) relative to fetal brain and adult cerebellum. Ephrin-B3, its putative ligand, shows higher expression in DAOY cells and fetal brain, and is present in 70-90% of SHH and non-SHH medulloblastomas (Sikkema et al., 2012). While its expression is relatively widespread, it has not been directly linked to oncogenic activity. This suggests ephrin-B3 may contribute to basal signaling dynamics rather than actively driving tumor progression (McKinney et al., 2015).

Similar to EphB3, EphB4 expression is downregulated in migratory medulloblastoma cells, suggesting an inverse relationship with invasion and a possible association with stem-like tumor phenotypes (Morrison et al., 2013). Among medulloblastoma cell lines, EphB4 expression was higher in DAOY and UW-426, whereas Res-256 exhibited minimal basal phosphorylation. Notably, ephrin-B1 stimulation significantly increased EphB4 phosphorylation in DAOY cells, indicating that its activation is ligand-dependent (Sikkema et al., 2012).

Microarray profiling of 29 medulloblastomas, validated in an additional cohort of 60 tumors, revealed that EphB4 is predominantly expressed in SHH-subtype tumors, with minimal expression in non-SHH variants. This pattern suggests a potential link between EphB4 and Sonic Hedgehog signaling, although its precise role in medulloblastoma biology remains to be defined (McKinney et al., 2015).

In NF2-null meningioma cell lines, kinome profiling revealed activation of Eph receptor tyrosine kinases (EphA2, EphB1), c-KIT, and the Src/SFK pathway, targets of the FDA-approved kinase inhibitor Dasatinib. These cells showed increased expression and phosphorylation of EphA2 and EphB1, along with elevated Src/SFK (Y416) phosphorylation. Dasatinib treatment (2h) significantly reduced phosphorylation of EphA2 (S897), EphB1 (Y594), and Src/SFK (Y416), without affecting mTORC1/2 activity. Transcriptomic analysis also showed elevated EphB1 and EphA4 expression. Variability in pEphA2, pEphB1, and pSrc/SFKs among tumors indicated intertumoral heterogeneity. Combined Dasatinib and dual mTORC1/2 inhibition led to stronger growth suppression, suggesting co-targeting Eph RTK/SFK and mTORC1/2 pathways may benefit NF2-deficient meningiomas (Angus et al., 2018).

Another study showed that NF2 loss activates autocrine NRG1-ERBB3 signaling, which interacts with EphA2 and mTORC1/2. In NF2-null human arachnoidal and Ben-Men-1 cells, NF2 deficiency increased NRG1 secretion and ERBB3 activation, promoting crosstalk with EphA2 and mTORC1/2. mTORC1/2 inhibition suppressed NRG1/ERBB3 signaling but triggered compensatory pAkt T308 activation via the IGF1R/insulin receptor. Dual blockade of mTORC1/2 and IGF1R/insulin signaling effectively reduced pAkt T308 and cell viability, supporting co-inhibition as a potential therapeutic strategy in NF2-deficient meningiomas (Beauchamp et al., 2021).